Literature DB >> 10623426

Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2.

Y Gazitt1, P Shaughnessy, W Montgomery.   

Abstract

TRAIL, the ligand for the newly discovered DR-4 and DR-5 receptor is a member of the tumour necrosis factor (TNF) family of death signal tranduction proteins with a mechanism of cell death, similar to the Fas and Fas ligand (Fas-L) system. Here, we provide first time evidence that TRAIL and TNF-alpha are potent inducers of apoptosis in multiple myeloma (MM) cell lines and freshly isolated myeloma cells. TRAIL effectively induced extensive apoptosis in 8226 and ARP-1 MM cells in a time- and dose-dependent manner reaching 80% within 48 h of treatment with a dose of 160 ng/ml. Bcl-2 transfected 8226 and ARP-1 cells were equally sensitive to apoptosis by TRAIL. Apoptosis with TNFalpha, reached >60% within 48 h of treatment with a dose of 160 ng/ml. In addition to MM cell lines, freshly isolated, flow-sorted myeloma cells from 8 different MM patients expressing variable levels of bcl-2 were equally sensitive to both TRAIL and TNF-alpha. We have previously shown that anti-Fas-induced apoptosis is not blocked by endogenous or ectopic bcl-2 in MM cell lines. Here we extend our observation with Fas to include TNF-alpha and TRAIL to the apoptotic signals that are not be blocked by bcl-2, in MM cells. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10623426     DOI: 10.1006/cyto.1999.0536

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  8 in total

1.  Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells.

Authors:  Carmen Ruiz-Ruiz; Abelardo López-Rivas
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

Review 2.  Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma.

Authors:  Quan Chen; Subrata Ray; Mohamad A Hussein; Gordan Srkalovic; Alexandru Almasan
Journal:  Leuk Lymphoma       Date:  2003-07

3.  Aggressive plasmablastic multiple myeloma in a 42-year-old: is inflammatory bowel disease or infliximab treatment to be blamed?

Authors:  Siddhartha Yadav; Ramesh Kumar; Ishmael A Jaiyesimi; Mohammad Muhsin Chisti
Journal:  BMJ Case Rep       Date:  2013-10-29

4.  Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients.

Authors:  E Stylianou; A Yndestad; L I Sikkeland; V Bjerkeli; J K Damås; T Haug; H G Eiken; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

Review 5.  Review article: multiple myeloma and inflammatory bowel disease.

Authors:  G Joel Reynolds; Kim A Annis; Willem J S de Villiers
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.199

6.  Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells.

Authors:  K-H Hung; S-T Su; C-Y Chen; P-H Hsu; S-Y Huang; W-J Wu; M-J M Chen; H-Y Chen; P-C Wu; F-R Lin; M-D Tsai; K-I Lin
Journal:  Cell Death Differ       Date:  2016-01-29       Impact factor: 15.828

7.  Crohn's disease and smoldering multiple myeloma: a case report and literature review.

Authors:  So Young Park; Jae Min Kim; Hyun Joon Kang; Minje Kim; Jae Joon Han; Chi Hoon Maeng; Sun Kyung Baek; Hwi-Joong Yoon; Si-Young Kim; Hyo Jong Kim
Journal:  Intest Res       Date:  2017-04-27

8.  Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2.

Authors:  I-K Kim; Y-K Jung; D-Y Noh; Y-S Song; C-H Choi; B-H Oh; E S Masuda; Y-K Jung
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.